SCHEMBL2122010

SCHEMBL2122010

COC(=O)c1ccc(Nc2c(-c3ccccn3)nc3c(C#N)c[nH]n23)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM5A P29375 7/20 0.50
▸ SMN1; SMN2 Q16637 5/20 0.40
▸ GAA P10253 4/20 0.40
▸ HTT P42858 3/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ METAP2 P50579 1/20 0.39
▸ KDM6B O15054 1/20 0.39
▸ KDM5C P41229 1/20 0.39
▸ KDM5D Q9BY66 1/20 0.39
▸ KDM4C Q9H3R0 1/20 0.39
▸ KDM5B Q9UGL1 1/20 0.39
▸ PHF8 Q9UPP1 1/20 0.39
▸ AURKA O14965 1/20 0.39
▸ MAPT P10636 6/20 0.38
▸ TP53 P04637 2/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2122989 0.87 KDM5A (0.48) KDM5ASMN1; SMN2KDM4EKDM6BKDM5C
SCHEMBL2124968 0.87 KDM5A (0.64) KDM5AKDM6BKDM5CKDM5DKDM4C
SCHEMBL2125864 0.85 KDM5A (0.62) KDM5AKDM6BKDM5CKDM5DKDM4C
SCHEMBL2127585 0.81 KDM5A (0.52) KDM5AKDM6BKDM5CKDM5DKDM4C
SCHEMBL2124057 0.80 MAPT (0.54) KDM5ASMN1; SMN2GAAKDM6BKDM5C
SCHEMBL2124147 0.80 MAPT (0.52) KDM5ASMN1; SMN2GAAHTTKDM6B
SCHEMBL2122331 0.79 ABCG2 (0.47) KDM5ASMN1; SMN2GAAHTTLMNA
SCHEMBL2123116 0.79 KDM5A (0.47) KDM5AMAPTTP53
SCHEMBL2132433 0.78 MAPT (0.41) KDM5ASMN1; SMN2GAAHTTLMNA
SCHEMBL2123600 0.77 KDM5A (0.41) KDM5AGAAHTTKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443123-B1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS INC (US) 2017-04-05 — — EP disclosed
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 — — US disclosed
EP-2443123-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) Rigel Pharmaceuticals, Inc. (US) 2012-04-25 — — EP disclosed
WO-2010147898-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS, INC. (US) 2010-12-23 — — WO disclosed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) SYK, BTK, LCK KDM5A 1592/4885SMN1; SMN2 2568/4885GAA 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback